Gandotinib

DB13040InvestigationalSmall molecule

Gandotinib has been used in trials studying the treatment of Myelofibrosis, Polycythemia Vera, Primary Myelofibrosis, Thrombocythemia, Essential, and Myeloproliferative Disorders, among others.

Mechanism: Pharmacologically active on Tyrosine-protein kinase JAK2
Curator reviewed
Formula / weight: C₂₃H₂₅ClFN₇O · 469.95 g/mol (avg)
Also known as: 3-(4-CHLORO-2-FLUOROBENZYL)-2-METHYL-N-(5-METHYL-1H-PYRAZOL-3-YL)-8- (MORPHOLINOMETHYL)IMIDAZO(1,2-B)PYRIDAZIN-6-AMINE · Adenosine triphosphate type 1 competitive inhibitor of JAK2 V617F tyrosine kinase · IMIDAZO(1,2-B)PYRIDAZIN-6-AMINE, 3-((4-CHLORO-2-FLUOROPHENYL)METHYL)-2-METHYL-N-(5- METHYL-1H-PYRAZOL-3-YL)-8-(4-MORPHOLINYLMETHYL)-
Code names: LY-2784544

Resolves to

Compound

UNIIANC71R916OCAS1229236-86-5ChEMBLCHEMBL2107823ChEBI188757PubChem46213929

Structure

InChIKeySQSZANZGUXWJEA-UHFFFAOYSA-NSMILESCC1=CC(NC2=NN3C(CC4=CC=C(Cl)C=C4F)=C(C)N=C3C(CN3CCOCC3)=C2)=NN1

Targets

O60674JAK2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Gandotinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account